ClinicalTrials.gg

Program

Boostrix

Also written as “Boostrix™”, “Boostrix®” and “Tdap vaccine”.

Its studies are mostly in Tetanus · Diphtheria · Whooping Cough · Respiratory Syncytial Virus Infections · Herpes Zoster, led by 4 companies.

Furthest: phase 4, since Jan 25, 200625 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline200 open or runningphase 4since Jan 25, 2006Jan 25, 2006none ahead
Changchun BCHT Biotechnology22 open or runningphase 2since Aug 4, 2026Mar 19, 2026none ahead
Sanofi20 open or runningphase 4since Apr 28, 2006Apr 28, 2006none ahead
Novartis10 open or runningphase 3since Aug 17, 2007Aug 17, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Jan 25, 2006.

  1. Jan 13, 2011Phase 3 study in TetanusGlaxoSmithKline · NCT01277705 · 806 enrolled
  2. Feb 10, 2011Phase 4 study in TetanusGlaxoSmithKline · NCT01294605 · 460 enrolled · Belgium, Netherlands, Spain
  3. Nov 21, 2012Phase 3 study in TetanusGlaxoSmithKline · NCT01738477 · 165 enrolled · United States
  4. Dec 21, 2012Phase 3 study in Meningococcal InfectionsGlaxoSmithKline · NCT01767376 · 692 enrolled · Dominican Republic, Germany, Korea, Republic of
  5. Nov 14, 2013Phase 3 study in DiphtheriaGlaxoSmithKline · NCT01988857 · 302 enrolled · Vietnam
  6. Jan 23, 2014Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02052596 · 935 enrolled · United States
  7. Feb 20, 2014Phase 4 study in Whooping CoughGlaxoSmithKline · NCT02072525 · 359 enrolled · Canada
  8. Feb 26, 2015Phase 4 study in Diphtheria-Tetanus-acellular Pertussis VaccinesGlaxoSmithKline · NCT02377349 · 688 enrolled · Australia, Canada, Czechia and more
  9. Oct 6, 2017Phase 3 study in DiphtheriaGlaxoSmithKline · NCT03311659 · 448 enrolled · Russian Federation
  10. May 20, 2019Phase 1 study in Tetanus Immunisation (Healthy Volunteers)Sanofi · NCT03958799 · 71 enrolled · Canada
  11. Oct 22, 2019Phase 2 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT04138056 · 509 enrolled · United States, Belgium, Canada
  12. Dec 10, 2021Phase 3 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT05169905 · 9 enrolled · United States
  13. Mar 19, 2026Changchun BCHT Biotechnology's first study: phase 1 study in Whooping CoughNew to Changchun BCHT BiotechnologyChangchun BCHT Biotechnology · NCT07492303 · 96 planned
  14. Aug 4, 2026Phase 2 study in Whooping CoughPhase 2 reachedChangchun BCHT Biotechnology · NCT07894055 · 420 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07894055Whooping Cough · China2RecruitingChangchun BCHT BiotechnologySep 25, 2026420
NCT07492303Whooping Cough1Not yet recruitingChangchun BCHT BiotechnologyJul 10, 202696
NCT05169905Respiratory Syncytial Virus Infections · United States3CompletedGlaxoSmithKlineAug 3, 20229
NCT04138056Respiratory Syncytial Virus Infections · United States, Belgium, Canada2CompletedGlaxoSmithKlineFeb 25, 2020509
NCT03958799Tetanus Immunisation (Healthy Volunteers) · Canada1CompletedSanofiApr 6, 202171
NCT03311659Diphtheria · Russian Federation3CompletedGlaxoSmithKlineAug 31, 2018448
NCT02377349Diphtheria-Tetanus-acellular Pertussis Vaccines · Australia, Canada, Czechia and more4CompletedGlaxoSmithKlineAug 14, 2017688
NCT02072525Whooping Cough · Canada4CompletedGlaxoSmithKlineJun 2, 2015359
NCT02052596Herpes Zoster · United States3CompletedGlaxoSmithKlineJun 16, 2015935
NCT01988857Diphtheria · Vietnam3CompletedGlaxoSmithKlineMay 10, 2014302
NCT01767376Meningococcal Infections · Dominican Republic, Germany, Korea, Republic of3CompletedGlaxoSmithKlineJan 16, 2014692
NCT01738477Tetanus · United States3CompletedGlaxoSmithKlineApr 2, 2014165
NCT01294605Tetanus · Belgium, Netherlands, Spain4CompletedGlaxoSmithKlineSep 2004460
NCT01277705Tetanus3CompletedGlaxoSmithKlineApr 2002806
NCT01147900Tetanus · Belgium4CompletedGlaxoSmithKlineMay 8, 2012180
NCT00835237Tetanus · United States3CompletedGlaxoSmithKlineJul 23, 20091,332
NCT00548171Tetanus · Australia4CompletedGlaxoSmithKlineApr 30, 2008203
NCT00544271Tetanus · Australia4TerminatedGlaxoSmithKline720
NCT00518180Meningitis, Meningococcal · Costa Rica3CompletedNovartisApr 20081,620
NCT00452686Diphtheria · China3CompletedGlaxoSmithKline660
NCT00406562Tetanus · China3CompletedGlaxoSmithKline30
NCT00385255Diphtheria · United States3CompletedGlaxoSmithKlineFeb 28, 20071,726
NCT00346073Diphtheria · United States3CompletedGlaxoSmithKlineMar 1, 20072,337
NCT00319553Whooping Cough · United States4CompletedSanofiOct 2008647
NCT00282295Tetanus · United States4CompletedGlaxoSmithKlineAug 8, 20061,344

How it is read

Names in the registry

  • “Boostrix™”, 6 entries
  • “Boostrix”, 5 entries
  • “Boostrix®”, 5 entries
  • “Tdap vaccine”, 2 entries
  • “Boostrix-US”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.